Mabqi is a high-tech developer of human therapeutic antibodies. Its phage display core technology platform allows the development of functional antibodies (including pH-sensitive antibodies selected from our oncology-dedicated library) with high developability through proprietary synthetic human libraries. Based on the technical expertise built on more than 20 successful discovery programs (Servier, ADC Therapeutics, … ) and the clinical expertise of its Medical Advisory Board, Mabqi is actively building a portfolio of first-in-class and best-in-class proprietary antibodies with high therapeutic potential in oncology.

Some of these assets are already available for partnered development and licensing opportunities. Mabqi provides also customized discovery services, including full antibody characterization, and has developed a unique and dedicated library to select pH-dependent antibodies for oncology indications.

Thanks to smooth integration of high throughput discovery processes and AI, Mabqi is able to propose a portfolio of outstanding, readily developable antibodies: Tumor Microenvironment Targeting through pH sensitivity, excellent affinity ranges on membrane proteins and biological functionality are combined to offer solutions even in the most complicated cases.

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Montpellier (FRANCE)

–  Employees: 11-50

–  Created in: 2017

StromaCare is a biotech company specialized in discovering and developing new cancer treatments through their understanding of stromal tissue biology. They develop innovative oncology drugs, both as standalone treatments and in combination with other therapies, for treating solid tumors based on the novel approach of modulating stromal components. How cancer develops and progresses is linked to the tumor stroma. The stroma limits the efficiency of immune cells against tumor cells, facilitates the migration of tumor cells, and prevents the access of treatments to the tumor.

At StromaCare, they aim to make the stroma ‘permeable’ to immune cells and other molecules of interest to eliminate the tumor.

StromaCare identified a set of stromal players and characterized their roles. Their lead drug candidate, STRO-501, a monoclonal antibody, targets a key stromal player called βig-h3, which is common to most cancers and serves as a novel T-cell regulator. This lead monoclonal antibody has demonstrated strong efficacy in preclinical studies, shows a favorable safety profile, and has received a favorable opinion from the EMA. StromaCare aims to start their clinical trial in 18 to 24 months, either as a standalone treatment or in combination with anti-PD1 in resistant cancers.

Their pipeline includes other targets and antibodies addressing different aspects of stromal biology.

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Lyon (FRANCE)

–  Employees: 11 – 50

– Created in: 2022